Imugene Ltd · ASX:IMU
Imugene — Shareholder Meeting (August 2025)
6 slides from Imugene's shareholder meeting presentation, Aug 20, 2025
Slide 1: Extraordinary General Meeting
ASX:IMU For personal use only Extraordinary General Meeting Wednesday, 20 August 2025 1 Release authorised by the Managing Director and Chief Executive Officer, Imugene Limited.
Slide 2: Disclaimer
Disclaimer The information in this presentation does not constitute personal Neither the Company nor any of its directors, officers, employees, investment advice. The presentation is not intended to be advisers, associated persons or subsidiaries are liable for any direct, comprehensive or provide a
Slide 3: Imugene is a clinical stage cancer company developing three drug products
Imugene is a clinical stage cancer company developing three drug products in CAR T cell therapy and oncolytic viruses onCARlytics CD19 For personal use only azer-cel CD19 allo CAR T CF33 Oncolytic Virus expressing virus Phase 1b Phase 1 VAXINIA MAST Trial Phase 1 OASIS Trial Off-the-shelf drug, aka
Slide 4: Azer-cel 79% Overall Response Rate
Azer-cel 79% Overall Response Rate N=14 For personal use only Best Response CR CR CR CR CR CR PR PR PR PR PR SD SD PD Durability 470+ 350+ *210+ 95+ 90 90 60+ 60 30+ 30+ 30+ Days Days Days Days Days Days Days Days Days Days Days *Allo transplant at Day 148 Overall Response Rate (ORR): the proportion
Slide 5: Expected Key Catalysts
Expected Key Catalysts Rich News flow 12 months ahead across Imugene’s programs Key Achievements Expected Upcoming Milestones For personal use only azer-cel azer-cel January 2025: First Aus site 3Q CY25 opened for DLBCL clinical trial and • Release of additional Phase 1b azer-cel data first DLBCL pa
Slide 6: For personal use only
ASX : IMU For personal use only shareholderenquiries@imugene.com imugene.com 6